ArticleScience immunology2018
Islet-reactive CD8
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.
0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed
25.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 255 citations in OpenAlex.
- Trial
- Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry.Frontiers in immunology · 2019Trial
- Going to the source: pancreatic lymph nodes maintain stem-like CD8+ T cells in human type 1 diabetes.The Journal of clinical investigation · 2026Article
- The central role of the β-cell in diabetes: from monogenic forms to type 1, type 2, and gestational diabetes.Reviews in endocrine & metabolic disorders · 2026Review
- From Disposal to Display: Crinophagy as a β-Cell Source of Neoantigens in Type 1 Diabetes.Immunological reviews · 2026Review
- Gut Microbiota Regulates Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes by Targeting PF4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Generation of Regulatory T Cells Against Islet Neoantigen.European journal of immunology · 2026Article
- Coxsackievirus B escapes antiviral CD8Science advances · 2026Article
- Modeling immune responses to autologous and allogeneic human stem cell-derived islet grafts in vivo.JCI insight · 2026Article
- Upregulation of ADAM19 in dendritic cells is associated with immune features and lower C-peptide levels in type 1 diabetes mellitus.Diabetology & metabolic syndrome · 2026Article
- Dual CD8 and TCR editing in regulatory T cells mediates HLA-A2-restricted tissue-specific homing.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- New and emerging therapies in type 1 diabetes mellitus.The Journal of clinical investigation · 2026Review
- Review
- Identification of a type 1 diabetes-associated T cell receptor repertoire signature from the human peripheral blood.Science advances · 2026Article
- Integrated histopathology of the human pancreas throughout stages of type 1 diabetes progression.Nature communications · 2026Article
- Quantitative V gene-targeted T cell receptor sequencing as a biomarker in type 1 diabetes.JCI insight · 2026Article
- Immunogenetics and TCR expression patterns together predict future T1D onset from multi-omic datasets.Frontiers in genetics · 2026Article
- Small things matter: Lack of extraislet β cells in type 1 diabetes.Science advances · 2025Article
- Molecular and Inflammatory Etiologies of β-Cell Dysfunction in Type 1 Diabetes.Physiology (Bethesda, Md.) · 2025Review
- Post-Translational Modified Neoantigens in Autoimmune Diseases: Challenges of Immune Tolerance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 13 institutions in 5 countries.
Slobodan CulinaINSERM, U1016, Cochin Institute, Paris, France.ORCID 0000-0001-6461-6953
Ana Ines LalanneINSERM, U1016, Cochin Institute, Paris, France.ORCID 0000-0003-3898-5426
Georgia AfonsoINSERM, U1016, Cochin Institute, Paris, France.
Karen CerosalettiBenaroya Research Institute, Translational Research Program, Seattle, WA 98101, USA.ORCID 0000-0002-7403-6239
Sheena PintoDivision of Developmental Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Guido SebastianiDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, and Fondazione Umberto di Mario ONLUS, Toscana Life Sciences, Siena, Italy.ORCID 0000-0003-4374-8564
Klaudia KurandaINSERM, U1016, Cochin Institute, Paris, France.ORCID 0000-0002-7526-628X
Laura NigiDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, and Fondazione Umberto di Mario ONLUS, Toscana Life Sciences, Siena, Italy.ORCID 0000-0002-6251-3069
Anne EugsterCRTD-DFG Research Center for Regenerative Therapies Dresden, Medical Faculty, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0001-8009-5959
Thomas ØsterbyeDepartment of International Health, Immunology and Microbiology, Panum Institute, Copenhagen, Denmark.ORCID 0000-0002-1449-8036
Alicia MaugeinINSERM, U1016, Cochin Institute, Paris, France.ORCID 0000-0001-8721-288X
James E McLarenDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Kristin LadellDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Etienne LargerINSERM, U1016, Cochin Institute, Paris, France.ORCID 0000-0002-1017-1845
Jean-Paul BeressiCentre Hospitalier de Versailles André Mignot, Service de Diabétologie, Le Chesnay, France.ORCID 0000-0003-4938-5610
Anna LissinaPierre et Marie Curie Paris 6 University, Sorbonne Paris Cité, Département Hospitalo-Universitaire FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
Victor AppayPierre et Marie Curie Paris 6 University, Sorbonne Paris Cité, Département Hospitalo-Universitaire FAST, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
Howard W DavidsonBarbara Davis Center for Diabetes and Integrated Department of Immunology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-5605-3812
Søren BuusDepartment of International Health, Immunology and Microbiology, Panum Institute, Copenhagen, Denmark.
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Matthias KuhnInstitut für Medizinische Informatik und Biometrie, Medical Faculty, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0003-2868-5155
Ezio BonifacioCRTD-DFG Research Center for Regenerative Therapies Dresden, Medical Faculty, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-8704-4713
Manuela BattagliaDiabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0003-4535-3152
Sophie Caillat-ZucmanAssistance Publique Hôpitaux de Paris, Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.
Francesco DottaDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, and Fondazione Umberto di Mario ONLUS, Toscana Life Sciences, Siena, Italy.
Raphael ScharfmannINSERM, U1016, Cochin Institute, Paris, France.
Bruno KyewskiDivision of Developmental Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Roberto MalloneINSERM, U1016, Cochin Institute, Paris, France. roberto.mallone@inserm.fr.ORCID 0000-0002-9846-8861
ImMaDiab Study Group
Délégation Paris 5 · FRFondazione Umberto Di Mario · ITGerman Cancer Research Center · DEHôpital Saint-Louis · FRInserm · FRCardiff University · GBTechnische Universität Dresden · DEHôpital André Mignot · FRInstitute of Translational Health Sciences · USInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DENational Institutes of Health · USUniversity of Colorado Anschutz Medical Campus · USVita-Salute San Raffaele University · IT
Funding
Northwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2001 to 2018
$10.3MType I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5MUCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1MType 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · PI MORAN, ANTOINETTE M. · 2009 to 2018
$7.1MPrediction and Prevention of Type I DiabetesU01DK061058 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2018
$6.5MTrialNet: University of Florida Clinical Center and NetworkU01DK085461 · NIDDK · UNIVERSITY OF FLORIDA · PI HALLER, MICHAEL JAMES · 2009 to 2018
$5.9MTrialNet: Diabetes Type 1 PreventionU01DK085509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GOTTLIEB, PETER A · 2009 to 2018
$5.8MType 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1DU01DK085499 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BAIDAL, DAVID · 2009 to 2018
$4.9MVanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNetU01DK085465 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUSSELL, WILLIAM E · 2009 to 2018
$4.8MType 1 Diabetes TrialNet: Clinical Center at Yale University (U01)U01DK085466 · NIDDK · YALE UNIVERSITY · PI HEROLD, KEVAN C · 2009 to 2018
$3.3MMOLECULAR TARGETS OF CMI IN TYPE I DIABETESR01DK052068 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DAVIDSON, HOWARD W · 1997 to 2014
$3.1MType 1 Diabetes TrialNet at Indiana University Clinical CenterU01DK085505 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DIMEGLIO, LINDA A · 2009 to 2013
$3.0MNIDDK NIH HHS R01 DK052068NIDDK NIH HHS R56 DK052068NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085453NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085463NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085504NIDDK NIH HHS U01 DK085505NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK103180NIDDK NIH HHS U01 DK103266Wellcome Trust
Abstract
The human leukocyte antigen-A2 (HLA-A2)-restricted zinc transporter 8
Indexed as
AdultCD8-Positive T-LymphocytesCell LineChildDiabetes Mellitus, Type 1FemaleHealthy VolunteersHLA-A2 AntigenHumansIslets of LangerhansMalePancreasHLA-A2 Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.